On Friday, Shares of Merit Medical Systems, Inc. (NASDAQ:MMSI), gained 13.79% to $25.17.
Merit Medical Systems, declared record revenues of $138.1 million for the quarter ended June 30, 2015, an enhance of 7% over revenues of $128.9 million for the quarter ended June 30, 2014. Revenues for the six-month period ended June 30, 2015 were a record $267.7 million, contrast to $248.1 million for the corresponding period in 2014, an enhance of 8%. The growth of revenues in constant currency would have been 10% for both the quarter and the six months ended June 30, 2015.
Merit’s non-GAAP net income for the quarter ended June 30, 2015 was $10.9 million, up 70%, or $0.25 per share, contrast to $6.4 million, or $0.15 per share, for the quarter ended June 30, 2014.
Merit Medical Systems, Inc. designs, develops, manufactures, and markets medical devices for interventional and diagnostic procedures worldwide. The company’s Cardiovascular segment offers cardiology and radiology devices for diagnosing and treating coronary arterial, peripheral vascular, and other non-vascular diseases; and embolotherapeutic products.
Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), declined -4.09% to $125.50, during its last trading session.
Vertex Pharmaceuticals Incorporated, declared that the U.S. Food and Drug Administration (FDA) approved ORKAMBI (lumacaftor/ivacaftor), the first medicine to treat the underlying cause of cystic fibrosis (CF) in people ages 12 and older with two copies of the F508del mutation. It is only indicated for these patients, who can be identified with a genetic test.
Cystic fibrosis is a rare, life-threatening genetic disease. People with two copies of the F508del mutation represent the largest group of people with CF. Of the 30,000 people in the United States with CF, about 8,500 ages 12 and older have two copies of the F508del mutation. ORKAMBI will be accessible for shipment to specialty pharmacies in the United States within days.
Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases in specialty markets. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF); and advancing its research and early-stage development programs.
At the end of Friday’s trade, Shares of Biomed Realty Trust Inc (NYSE:BMR), lost 0.74% to $20.45.
BioMed Realty Trust, declared it will report results for its second quarter ended June 30, 2015 after the market closes on Tuesday, July 28, 2015.
Alan D. Gold, Chairman, President and Chief Executive Officer, and other members of the BioMed Realty administration team will host an investor conference call at 10:00 a.m. Pacific Time on Wednesday, July 29, 2015 to talk about the company’s financial results and operations for the quarter.
BioMed Realty Trust, Inc. operates as a real estate investment trust (REIT) that focuses on providing real estate to the life science industry in the United States. Its tenants primarily comprise biotechnology and pharmaceutical companies, scientific research institutions, government agencies, and other entities involved in the life science industry.
Finally, LKQ Corporation (NASDAQ:LKQ), ended its last trade with -1.59% loss, and closed at $30.90.
LKQ Corporation, will release second quarter 2015 financial results before the market opens on Thursday, July 30, 2015.
LKQ Corporation, together with its auxiliaries, distributes replacement parts, components, and systems used in the repair and maintenance of vehicles in the United States, the United Kingdom, the Netherlands, Belgium, Northern France, Canada, Mexico, and Central America. The company operates in four segments: WholesaleNorth America, WholesaleEurope, Self Service, and Specialty.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
